Tag: RET Mutations

Home / RET Mutations

Categories

Selpercatinib is approved by the USFDA for medullary thyroid cancer with a RET mutation

 On September 27, 2024, the Food and Drug Administration conferred traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients aged 2 years and older diagn...
ret-mutations

Scan the code